Research
-
January 27, 2022
Impaired neutrophils in autoimmunity
Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity. -
January 20, 2022
New method enhances efforts to identify drug repurposing targets
Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use. -
January 20, 2022
Omicron evades some but not all monoclonal antibodies: study
A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. -
January 19, 2022
Study identifies molecular trigger of severe injury-induced inflammatory response
Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure. -
January 18, 2022
Ensuring the “best possible” medication history
About 80% of hospital admission electronic records were missing a drug prescribed to an older adult, Vanderbilt researchers found, highlighting the need for a multipronged approach to address medication discrepancies and support safe prescribing practices. -
January 17, 2022
H. pylori, lipid loss and stomach cancer
H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered. -
January 14, 2022
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.